---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000012"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:51:03.171509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025

## Summary
- IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.
- IMM-1-104 + mFFX in 1L pancreatic: all 4 patients had tumor shrinkage; 1 partial response with 100% target lesion reduction.
- IMM-1-104 monotherapy in 2L pancreatic: 11 of 21 evaluable patients achieved disease control; 1 partial response with 67% reduction.
- IMM-6-415 Phase 1 PK/PD: up to 77% pERK inhibition; generally well tolerated with no dose-limiting toxicities.
- Additional Phase 2a data expected Q2 2025; plans to launch arms in melanoma and NSCLC with combinations.

## SEC filing metadata
- accession: 0001790340-25-000012
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/0001790340-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/imrx-20250107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000012
- JSON: https://secwatch.observer/filing/0001790340-25-000012.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.